Sort   by:  
 Page size 
UnknownThe Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Not available
S-EPMC7409133 | biostudies-literature
UnknownClinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
Not available
S-EPMC10485401 | biostudies-literature
UnknownPhase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.
Not available
S-EPMC10649956 | biostudies-literature
UnknownOutcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.
Not available
S-EPMC11106362 | biostudies-literature
UnknownA three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma.
Not available
S-EPMC11039903 | biostudies-literature
UnknownReal-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.
Not available
S-EPMC12664163 | biostudies-literature
UnknownCabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Not available
S-EPMC10257898 | biostudies-literature
Sort   by:  
 Page size